Expert: FDA guidance for Alzheimer's drugs should help industry

02/9/2013 | Columbus Dispatch (Ohio), The

New draft guidance for the development of drugs targeting the early stages of Alzheimer's disease will assist drugmakers with the design of clinical trials aimed at detecting disease before the onset of dementia, said Dr. Paul Aisen, director of the Alzheimer's Disease Cooperative Study. "I think this will be hugely useful to the pharmaceutical industry," he said.

View Full Article in:

Columbus Dispatch (Ohio), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD